Tasly Forges $22 Million Partnership with France's Pharnext

China's Tasly Pharma formed a partnership with Pharnext SA (Paris: ALPHA), a French company that combines and repositions approved drugs to develop innovative therapies. The agreement has three parts: Tasly will invest $22 million in Pharnext; the two companies will form a JV to develop new drugs using Pharnext's platform; and Tasly acquired China rights to Pharnext's lead drug candidate, a treatment for Charcot-Marie-Tooth disease type 1A. Tasly will contribute its knowledge of traditional Chinese medicines to the combination drug development JV. More details.... Stock Symbol: (SHA: 600535) Share this with colleagues: // //